Navigation Links
H. pylori vaccine shows promise in mouse studies

Researchers from Southern Medical University in Guangdong, Guangzhou, China, have developed an oral vaccine against Helicobacter pylori, the bacteria responsible for peptic ulcers and some forms of gastric cancer, and have successfully tested it in mice. The research is published ahead of print in the journal Clinical and Vaccine Immunology.

The investigators constructed a live recombinant bacterial vaccine, expressing the H. pylori antigen, adhesin Hp0410, in the food-grade bacterium, Lactobacillus acidophilus. They then used it to orally vaccinate the mice.

The vaccine elicited specific anti-Hp0410 IgG antibodies in serum, and showed "a significant increase" in the level of protection against gastric Helicobacter infection, according to the report. When assayed, following challenge with H. pylori, immunized mice had significantly lower bacterial loads than non-immunized mice.

H. pylori is a class 1 human carcinogen, according to the World Health Organization. It causes gastritis, peptic ulcers, stomach cancer, and mucosa-associated lymphoid tissue lymphoma. Antibiotic therapy is complex, unsuccessful in some patients (particularly in developing countries) and relapse is common. A vaccine against H. pylori could circumvent these difficulties.

L. acidophilus, a bacterium which is common in yogurt cultures, has distinct advantages as an oral vaccine antigen delivery vehicle. It is safe and nontoxic. It resists the stomach's acidity and tolerates bile, all of which aids in enabling it to survive in the gastrointestinal (GI) tract for more than 72 hours. Additionally, it adheres to, and elicits an immune response from the GI tract mucosa.

The current first-line treatment option for H. pylori infection includes two antibiotics and a proton pump inhibitor, but is ineffective in roughly 20 percent of patients.

"The high cost of treatment, noncompliance, and antibiotic resistance are the most important reasons," says first author Fan Hongying.

Roughly 15-30 percent of patients relapse quickly, she says, noting that after treatment, H. pylori may be resupplied to the stomach from a reservoir in the mouth. A vaccine would circumvent these problems.

"Our results collectively indicate that adhesin Hp0410 is a promising candidate vaccine antigen and recombinant Lactobacillus acidophilus expressing Hp0410 is likely to constitute an effective, low-cost live bacterial vaccine against H. pylori," says Hongying.


Contact: Jim Sliwa
American Society for Microbiology

Related biology news :

1. Ironing out the link between H. pylori infection and gastric cancer
2. Special issue of Gut Microbes on Helicobacter pylori
3. Queens scientists seek vaccine for Pseudomonas infection
4. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
5. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
6. SFU HIV/AIDS vaccine research gets financial boost
7. Researchers identify Achilles heel of dengue virus, target for future vaccines
8. AAPS National Biotechnology Conference to highlight innovative vaccines
9. Army study: DNA vaccine and duck eggs protect against hantavirus disease
10. Sensitive test helps improve vaccine safety
11. Overweight? Theres a vaccine for that
Post Your Comments:
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... adds 2016 global ... pharmaceuticals section with historic and forecast data along ... Complete report on the Cell Culture ... companies and supported with 261 tables and figures ... The Global Cell Culture Media Industry ...
Breaking Biology Technology: